World Library  
Flag as Inappropriate
Email this Article

Meclizine

 

Meclizine

Meclizine
Systematic (IUPAC) name
(RS)-1-[(4-chlorophenyl)(phenyl)methyl]-4-(3-methylbenzyl)piperazine
Clinical data
MedlinePlus
Pregnancy cat.
Legal status
Routes Oral, sublingual/buccal
Pharmacokinetic data
Metabolism hepatic
Half-life 6 hours
Identifiers
CAS number  YesY
ATC code R06
PubChem
IUPHAR ligand
DrugBank
ChemSpider  YesY
UNII  YesY
ChEMBL  N
Chemical data
Formula C25H27ClN2 
Mol. mass 390.948 g/mol
Physical data
Boiling point 230 °C (446 °F)
 N   

Meclizine (INN,[1] or meclozine) is an antihistamine considered to be an antiemetic. It is sold under the brand names Bonine, Bonamine, Antivert, Postafen, Sea Legs, and Dramamine (Less Drowsy Formulation). Emesafene is a combination of meclizine (1/3) and pyridoxine (2/3). In Canada, Antivert Tab (which is no longer available) was a combination of meclizine and nicotinic acid.[2]

Contents

  • Classification 1
  • Mechanism of action 2
  • Uses 3
    • Motion sickness 3.1
    • Vertigo 3.2
  • Side effects 4
    • Drowsiness 4.1
    • Special considerations in the elderly 4.2
  • Synthesis 5
  • Notes 6
  • References 7
  • External links 8

Classification

Meclizine is a first-generation antihistamine of the piperazine class. It is structurally and pharmacologically similar to buclizine, cyclizine, and hydroxyzine, but has a shorter half-life of six hours compared to cyclizine and hydroxyzine with about 20 hours (though half-life should not be confused with duration). It is used as an antivertigo/antiemetic agent, specifically in the prevention and treatment of nausea, vomiting, and dizziness associated with motion sickness.[3] Meclizine is sometimes combined with opioids, especially ones of the open-chain class like methadone, dextropropoxyphene, and dipipanone (originally combined with meclizine's parent drug cyclizine, the brand name of this combination is Diconal).

Mechanism of action

Meclizine is an antagonist at H1 receptors. It possesses anticholinergic, central nervous system depressant, and local anesthetic effects. Its antiemetic and antivertigo effects are not fully understood, but its central anticholinergic properties are partially responsible. The drug depresses labyrinth excitability and vestibular stimulation, and it may affect the medullary chemoreceptor trigger zone.[3] Meclizine also is a dopamine antagonist at D1-like and D2-like receptors, but does not cause catalepsy[note 1] in mice, perhaps because of its anticholinergic activity.[4]

Uses

Meclizine is approved by the U.S. Food and Drug Administration (FDA) to treat symptoms of motion sickness and for management of vertigo that stems from diseases affecting the vestibular system. Meclizine's safety and efficacy in children younger than 12 years old has not been established, therefore use in this population is not recommended. Also, meclizine should be taken with caution in the elderly (older than 65 years) because of increased risk of confusion and amnesia.[5]

Motion sickness

Meclizine is effective in inhibiting the symptoms of motion sickness, such as nausea, vomiting, and dizziness. The recommended dose is 25–50 mg orally, taken one hour before travel. The dose may be repeated every 6 hours as needed.[3]

The drug is also safe for treating nausea in pregnancy[6] and is a first-line therapy for this use.[7][8] Doxylamine is similarly safe.

Vertigo

Meclizine may be effective in relieving vertigo experienced as a result of inner ear infections or other conditions. The recommended dose is 25–100 mg per day orally, in divided doses.[3]

Side effects

Some common side effects such as drowsiness, dry mouth, and tiredness may occur. Meclizine has been shown to have fewer dry mouth side effects than the traditional treatment for motion sickness, transdermal scopolamine.[9] A very serious allergic reaction to this drug is unlikely, but seek immediate medical attention if it occurs. Symptoms of a serious allergic reaction may include: rash, itching/swelling, severe dizziness, and/or trouble breathing.[10]

Drowsiness

Drowsiness may result as a side effect of taking meclizine. Users are advised not to operate heavy machinery while under the influence. The consumption of alcohol while under the influence of meclizine may result in additional drowsiness.

Special considerations in the elderly

As with any anticholinergic agent, meclizine may cause confusion or aggravate symptoms in those with dementia in the geriatric population (older than 65 years). Therefore caution should be used when administering meclizine to the elderly.[11]

Synthesis

(4-Chlorphenyl)-phenylmethanol is halogenated with thionyl chloride before adding acetylpiperazine. The acetyl group is cleaved with diluted sulfuric acid. An N-alkylation of the piperazine ring with 3-methylbenzylchloride completes the synthesis.[12]

Alternatively, the last step can be replaced by a reductive N-alkylation with 3-methylbenzaldehyde. The reductive agent is hydrogen, and Raney nickel is used as a catalyst.[13][14]

Meclizine is obtained and used as a racemate, a 1:1 mixture of the two stereoisomers. Drug forms contain the dihydrochloride.

Notes

  1. ^ "[C]atalepsy was assessed by the bar method[:] the front paws were gently placed on a horizontal metal bar with 2 mm diameter suspended 4 cm above, and the length of time the mouse maintains this abnormal posture was measured."[4]

References

  1. ^ Guidelines on the Use of INNs for Pharmaceutical Substances (1997). Accessed November, 2013 "Guidance on INN." WHO.
  2. ^ DrugBank. Drugbank: Drug card for Meclizine David Wishard: University of Alberta, Canada. Accessed November 7, 2010.
  3. ^ a b c d Clinical Pharmacology. Clinical Pharmacology, revised November 20, 2009, accessed November 7, 2010.
  4. ^ a b Haraguchi K, Ito K, Kotaki H, Sawada Y, Iga T (1997). , and muscarinic acetylcholine receptor occupancies"2, D1"Prediction of drug-induced catalepsy based on dopamine D. Drug Metabolism and Disposition 25 (6): 675–684.  
  5. ^ MICROMEDEX 2.0. Accessed November 7, 2010.
  6. ^ Källén B, Mottet I (2003). "Delivery outcome after the use of meclizine in early pregnancy". European Journal of Epidemiology 18 (7): 665–669.  
  7. ^ "Antiemetische Therapie bei Schwangerschaftserbrechen" [Antiemetic therapy in pregnancy]. Arznei-Telegramm (in German) 40: 87–89. 2009. 
  8. ^ Embryotox: Meclozin (German)
  9. ^ Dahl E, Offer-Ohlsen D, Lillevold PE, Sandvik L. Transdermal scopolamine, oral meclizine, and placebo in motion sickness. Clinical Pharmacology And Therapeutics [Clin Pharmacol Ther] 1984 Jul; Vol. 36 (1), pp. 116-20. Available from: MEDLINE: Ipswich, MA. PMID 6734040
  10. ^ Meclizine - oral, Antivert, D-vert, Dramamine II. Accessed November 7, 2010.
  11. ^ Merck Manuals, Online Medical Library: Meclizine (Drug Information Provided by Lexi-Comp), revised January 2010, accessed November 7, 2010.
  12. ^ J.-H. Fuhrkop, G. Li (2003). Organic Synthesis. Concepts and Methods. Wiley. p. 237.  
  13. ^ US 2 709 169 (UCB, 1955)
  14. ^ A. Kleemann, J. Engel, B. Kutscher, D. Reichert (2001). Pharmaceutical Substances. Synthesis, Patents, Applications (4 ed.). Thieme.  

External links

  • University of Berlin's Institute of Biochemistry
  • Numark Pharmacies Information Page on Meclizine
  • Rxlist Medical Dictionary
This article was sourced from Creative Commons Attribution-ShareAlike License; additional terms may apply. World Heritage Encyclopedia content is assembled from numerous content providers, Open Access Publishing, and in compliance with The Fair Access to Science and Technology Research Act (FASTR), Wikimedia Foundation, Inc., Public Library of Science, The Encyclopedia of Life, Open Book Publishers (OBP), PubMed, U.S. National Library of Medicine, National Center for Biotechnology Information, U.S. National Library of Medicine, National Institutes of Health (NIH), U.S. Department of Health & Human Services, and USA.gov, which sources content from all federal, state, local, tribal, and territorial government publication portals (.gov, .mil, .edu). Funding for USA.gov and content contributors is made possible from the U.S. Congress, E-Government Act of 2002.
 
Crowd sourced content that is contributed to World Heritage Encyclopedia is peer reviewed and edited by our editorial staff to ensure quality scholarly research articles.
 
By using this site, you agree to the Terms of Use and Privacy Policy. World Heritage Encyclopedia™ is a registered trademark of the World Public Library Association, a non-profit organization.
 



Copyright © World Library Foundation. All rights reserved. eBooks from World eBook Library are sponsored by the World Library Foundation,
a 501c(4) Member's Support Non-Profit Organization, and is NOT affiliated with any governmental agency or department.